According to a report released by Daimo, full oral drugs from foreign companies have been added to the latest medical insurance catalogue, and treatment prices have dropped dramatically. However, not all of the oral and interferon treatment plans provided by Geli Pharmaceutical (01672) have not entered the medical insurance catalogue, which is extremely detrimental to Geli Pharmaceutical. The target price was drastically reduced by 63% from HK$10 to HK$3.7, and downgraded to the “synchronizing with the market” investment rating.

The bank expects a sharp decline in sales of Geli Pharmaceutical products, lowering the company's profit forecasts for 2020 to 2021 by 21% and 56% respectively. It is expected that hepatitis C patients in mainland China will use full oral treatment in 2022.